SAM-e arthritis treatment


How SAM-e works on Arthritis:

S-adenosyl-methionine is a natural substance that is almost present in the fluids and tissues of the human body. SAM-e reduces the pain, inflammation and stiffness associated with arthritis. SAM-e provides methyl molecules which are needed in producing the chemical compounds necessary for controlling pain, inflammation and the repair of cartilage. Studies done by Mayo Clinic in 2002 ( “Alternative Arthritis Treatments” ) showed that SAM-e may relieve the pain caused by osteoarthritis just as good as non-steroidal anti-inflammatory medications, like ibuprofen, but SAM-e use has fewer side effects.

SAM-e also helps fight depression by increasing the levels of serotonin which makes us feel good. SAM-e also helps in liver detoxification by increasing the amount of glutathione that removes the poison from alcohol damaged liver.

Side Effects and Precautions of SAM-e:

There are no reported interactions with other supplements or medications. Higher intake levels of SAM-e may lead to an increase in homocysteine which contributes to heart disease. To avoid conversion of SAM-e into homocysteine, take Vitamin B6@50mg, B12@1000mcg and Folic Acid@800mcg.

Forms, Dosage and Brand Names of SAM-e:

Adults: For joint health take 2 tablets a day (400mg) preferably on empty stomach 1 hour away from food. Increase the dosage up to 800mg as needed. Since SAM-e is unstable at high temperatures, it is best to keep this food supplement refrigerated.

Pregnant Women: Not recommended.

Children: Not recommended.

References about SAM-e and Arthritis:

Gutierrez S, et al. SAMe restores the changes in the proliferation and in the synthesis of fibronectin and proteoglycans induced by tumor necrosis factor alpha on cultured rabbit synovial cells. Brit Rheumatol 37: 27-31, 1997

Mansell JP, et al. Biochemical eveidence for altered subchondral bone collagen metabolism in osteoarthritis of the hip. Brit J Rheumatol 36:16-19, 1197

Osteoarthritis: the clinical picture, pathogenesis and management with studies on a new therapeutic agent, S-adenosylmethionine. Am J Med 83 (Suppl 5A) 1987 (Includes Numerous Studies).

Marcolongo R, et al. Double-blind multicentre study of activity of S-adenosylmethionine in hip and knee osteoarthritis. Curr Ther Res 37: 82-94

Tavoni A. et al Evaluation of S-adenosylmethionine in primary fibromyaglia: a double blind crossover study. Am J Med 83 (Suppl 5A): 107-110, 1987

Jacobsen S, et al Oral S-adenosylmethionine in primary fibroyaglia. Double-blind clinical evaluation. Scand J Rheumatol 20: 294-302, 1991

Fassbender HG, Role of chondrocytes in the development of osteoarthritis. Am J Med 83 (Suppl 5A):17-24, 1987

Comments are closed.